Commonly used commercial NGS platforms such as FoundationOne®CDx and Tempus xT are also performed on FFPE samples and reportedly detect, along with SNVs, insertions/deletions and copy number alterations for TP53, RB1, and PTEN, which may have demonstrated better tumor suppressor aberrancy and AVPCm detection [29,30]. The gene discussed is RB1; the disease is neoplasm.